Natural Killer Cells After Half-Matched Stem Cell Transplant for High-Risk AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new way to prevent leukemia from returning after a half-matched stem cell transplant. It uses specially activated natural killer cells to attack remaining cancer cells. This may help people with high-risk or relapsed AML who have few other options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have acute myeloid leukemia (AML) that is in remission (no visible cancer cells) or, if not in remission, must meet specific high-risk criteria like certain genetic changes.
- If you've had a previous stem cell transplant, you may still qualify under certain conditions.
- You must be 40 years old or younger.
- You need to have adequate organ function (liver, kidneys, heart, lungs).
- You must have a related donor who is a half-match (haploidentical) and meets health requirements.
- You must not have active graft-versus-host disease or other uncontrolled illnesses.
- You must agree to use contraception if applicable, and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early trial studies adding special immune cells called “natural killer cells” after a half-matched stem cell transplant for AML or MDS. The goal is to see if this approach improves outcomes and safety when there is no fully matched donor available.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
This trial tests a stem cell transplant using a half-matched donor, followed by extra immune cells and targeted drugs, for people with acute myeloid leukemia (AML) that is still active or has come back. The goal is to try to control the leukemia and improve outcomes.
Hear when a new AML, Childhood trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.